The Fas-based mechanism of lymphocytotoxicity

Human Immunology

Volumn 54, Issue 1, 1997, Pages 1-7

  Berke, Gideon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; LYMPHOCYTOTOXICITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THEORY;

ANIMALS; ANTIGENS, CD95; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031001834     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(97)00009-8     Document Type: Review

References (61)

1. Kägi D, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol. 14:1996;207.
2. Nagata S, Golstein P. The Fas death factor. Science. 267:1995;1449.
3. Berke G. The CTL's kiss of death. Cell. 81:1995;9.
4. Takayama H, Kojima H, Shinohara N. Cytotoxic T lymphocytes: the newly identified Fas (CD95)-mediated killing mechanism and a novel aspect of their biological functions. Adv Immunol. 60:1995;289.
5. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol. 12:1994;735.
6. Ginsburg H, Ax W, Berke G. Functional implications of cellular immunity. An analysis of graft reaction in cell cultures. Bertelli A, Monaco AP. Proceedings Symposium Pharmacological Treatment in Organ and Tissue Transplantation. 1970;85 Williams and Wilkins, Baltimore.
7. Russell JH, Dobos CB. Mechanisms of immune lysis. II. CTL-induced nuclear disintegration of the target begins within minutes of cell contact. J Immunol. 125:1980;1256.
8. Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Annu Rev Immunol. 10:1992;267.
9. Henkart PA. Mechanism of lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 3:1985;31.
10. Podack ER, Young JD, Cohn ZA. Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci USA. 82:1985;8629.
11. Henkart PA. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity. 1:1994;343.
12. Berke G. Lymphocyte-triggered internal target disintegration. Immunol Today. 12:1991;396.
13. Berke G, Rosen D. Circular lesions detected on membranes of target cells lysed by antibody and complement or natural killer (spleen) cells but not by in vivo primed cytolytic T lymphocytes. Bonavida B, Collier RJ. Membrane Mediated Cytotoxicity, UCLA Symposia, Park City. 1986;367 Alan R Liss, New York.
14. Berke G, Rosen D. Are lytic granules, and perforin 1 involved in lysis induced by in vivo primed, peritoneal exudate CTL? Transplant Proc. XIX:1987;412.
15. Berke G, Rosen D. Highly lytic in vivo primed CTL devoid of lytic granules and BLT-esterase activity acquire these constituents in the presence of T cell growth factors upon blast transformation in vitro. J Immunol. 141:1988;1429.
16. Berke G, Rosen D, Ronen D. Mechanism of lymphocyte-mediated cytolysis: functional cytolytic T cells lacking perforin and granzymes. Immunology. 78:1993;105.
17. Berthou C, Legros-Maida S, Soulie A, Wargnier A, Guillet J, Rabian C, Gluckman E, Sasportes M. Cord blood T lymphocytes lack constitutive perforin expression in contrast to adult peripheral blood T lymphocytes. Blood. 85:1995;1540.
18. Konjevic G, Schlesinger B, Cheng L, Olsen KJ, Podack ER, Spuzic I. Analysis of perforin expression in human peripheral blood lymphocytes, CD56+ natural killer cell subsets and its induction by interleukin-2. Immunol Invest. 24:1995;499.
19. Kaufmann Y, Berke G. Monoclonal cytotoxic T lymphocyte hybridomas capable of specific killing activity, antigenic responsiveness and inducible interleukin secretion. J Immunol. 131:1983;50.
20. Helgason CD, Prendergast JA, Berke G, Bleackley RC. Peritoneal exudate lymphocyte and mixed lymphocyte culture hybridomas are cytolytic in the absence of cytotoxic cell proteases and perforin. Eur J Immunol. 22:1992;3187.
21. Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 369:1994;31.
22. Liu CC, Walsh CM, Eto N, Clark WR, Young JD. Morphologic and functional characterization of perforin-deficient lymphokine-activated killer cells. J Immunol. 155:1995;602.
23. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 265:1994;528.
24. Kojima H, Shinohara N, Suda T, Hanaoka S, Someya-Shirota Y, Takaga Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, Shinkai T, Alt FW, Matsuzawa A, Yonehara S, Nagata S, Takayama H. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity. 1:1994;357.
25. Lowin B, Mattman C, Hahne M, Tschopp J. Comparison of Fas(Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes. Int Immunol. 8:1996;57.
26. Walsh CM, Matloubian M, Liu C-C, Ueda R, Kurahara CG, Christensen JL, Huang MTF, Young JD-E, Ahmed R, Clark WR. Immune function in mice lacking the perforin gene. Proc Natl Acad Sci USA. 91:1994;10854.
27. Walsh CM, Glass AA, Chiu V, Clark WR. The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J Immunol. 153:1994;2506.
28. 2+ independent T cell mediated cytotoxicity. J Exp Med. 177:1993;195.
29. Kägi D, Seiler P, Pavlovic J, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopatic viruses. Eur J Immunol. 25:1995;3256.
30. Heinkelein M, Pilz S, Jassoy C. Inhibition of CD95 (Fas/Apo1)-mediated apoptosis by vaccinia virus WR. Clin Exp Immunol. 103:1996;8.
31. Krammer PH, Behrmann I, Daniel P, Dhein J, Debatin KM. Regulation of apoptosis in the immune system. Curr Opin Immunol. 6:1994;279.
32. Engelmann H, Holtmann H, Brakebusch C, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem. 265:1990;14497.
33. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell. 74:1993;845.
34. Boldin MP, Mett IL, Varfolomeev EE, Chumakov I, Shemer-Avni Y, Camonis JH, Wallach D. Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for NTF and Fas/A PO1 effects. J Biol Chem. 270:1995;387.
35. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, de Villartay JP. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1995;1347.
36. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J Immunol. 156:1996;13.
37. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169.
38. Peitsch MC, Tschopp J. Comparative molecular modelling of the Fas-ligand and other members of the TNF family. Mol Immunol. 32:1995;761.
39. Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, et al. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1:1994;131.
40. Hahne M, Peitsch MC, Irmler M, Schroter M, Lowin B, Rousseau M, Bron C, Renno T, French L, Tschopp J. Characterization of the non-functional Fas ligand of gld mice. Int Immunol. 7:1995;1381.
41. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med. 179:1994;873.
42. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, Golstein P. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med. 181:1995;781.
43. Anel A, Simon AK, Auphan N, Buferne M, Boyer C, Golstein P, Schmitt-Verhulst AM. Two signaling pathways can lead to Fas ligand expression in CD8+ cytotoxic T lymphocyte clones. Eur J Immunol. 25:1995;3381.
44. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14:1995;1129.
45. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. Fas ligand in human serum. Nature Med. 2:1996;317.
46. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol. 25:1995;2303.
47. Glass A, Walsh CM, Lynch DH, Clark WR. Regulation of the Fas lytic pathway in cloned CTL. J Immunol. 156:1996;3638.
48. Griffith TS, Yu X, Herndon JM, Ferguson TA. CD95-induced apoptosis of lymphocytes immune privileged site induces immunol tolerance. Immunity. 5:1996;5.
49. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189.
50. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630.
51. Larsen CP, Alexander DZ, Hendrix R, Ritchie SC, Pearson TC. Fas-mediated cytotoxicity. Transplantation. 60:1995;221.
52. Schulz M, Schuurman HF, Joergensen J, Steiner C, Meerloo T, Kagi D, Hengartner H, Zinkernagel RM, Schreier MH, Burki K, et al. Acute rejection of vascular heart allografts by perforin-deficient mice. Eur J Immunol. 25:1995;474.
53. Barinaga M. Forging a path to cell death. Science. 273:1996;733.
54. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell. 81:1995;479.
55. Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME, Dixit VM. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem. 271:1996;4961.
56. Stanger BZ, Leder P, Lee T-H, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 81:1995;513.
57. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell. 85:1996;803.
58. Tewari M, Quan NT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier G, Salvesen GS, Dixit VM. Yama/CPP32b, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP)-ribose-polymerase. Cell. 81:1995;801.
59. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin TT, Yu VL, Miller DK. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37.
60. Enari M, Talanian RV, Wong WW, Nagata S. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature. 380:1996;723.
61. Weis M, Schlegel J, Kass GE, Holmstrom TH, Peters I, Eriksson J, Orrenius S, Chow SC. Cellular events in Fas/APO-1-mediated apoptosis in JURKAT T lymphocytes. Exp Cell Res. 219:1995;699.